Lymphatic malformations (LM) are a congenital malformation of lymphatic vessels. This type of pathology is rare and occurs in 1,2-2,8 per 1000 of live newborns. According to the classification of the International Society for the Study of Vascular Anomalies (ISSVA), LMs are vascular malformations with slow flow characteristics. LM major complications are: inflammation in the malformation cavity, hemorrhage, progressive increase (a threat of compression of large vessels, respiratory tract, intestinal loops). Clinically, LM manifests itself as a volumetric formation of doughy consistency, which gradually increases
in size. Sclerotherapy is the advanced minimally invasive LM treatment method. Surgical removal of pathological tissues by the "open method" is also practiced, but due to the risk of recurrence, as well as a large volume of removal, resulting in the formation of large scars, this method is used less frequently, mainly when removing single-chamber large-cystic LMs, which are also mistakenly called "cystic hygromas". Special sclerosing agents such as Doxycycline, Bleocyne, Picibanil (OK-432) and other drugs are used for sclerosing of LM. Due to the special characteristics of the impact of each drug on the endothelium, during the early post-surgical period there occur various undesirable effects (swelling, pain conditions, toxic effects, allergies, etc.), moreover, the effectiveness of the used sclerosing agents is not always sufficient to obtain a good clinical effect.